© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
The Foresee PHP, a second-generation Preferential Hyperacuity Perimeter is available for improved detection and early diagnosis of the most aggressive and sight-threatening form of age-related macular degeneration (AMD). Developed by Notal Vision and distributed exclusively in the United States by MSS, the device represents a technologic leap for monitoring AMD and is a clinically validated diagnostic device for improved early detection of choroidal neovascularization (CNV).
The Foresee PHP, a second-generation Preferential Hyperacuity Perimeter, is available for improved detection and early diagnosis of the most aggressive and sight-threatening form of age-related macular degeneration (AMD). Developed by Notal Vision and distributed exclusively in the United States by MSS, the device represents a technologic leap for monitoring AMD and is a clinically validated diagnostic device for improved early detection of choroidal neovascularization (CNV).
The device is the follow-up to the Preview PHP and allows eye-care professionals to track any changes to a patient's visual field resulting from the advancement of AMD. The updated device is completely automated, allowing for patient self-operation, while still exhibiting high sensitivity and specificity. The Foresee PHP also has a larger normative database, provides faster testing and test analysis, and generates advanced reports that feature a map of the patient's visual field indicating the relative location of abnormalities in the macular area.
The Foresee PHP maps defects within a patient's visual field by analyzing responses to "dot deviation signals" flashing on a computer screen. The patient uses a stylus pen to touch the screen to identify the most prominent distortion in the line. The response patterns are recorded, analyzed and compared with the normative database, producing a report revealing the relative location of the defects in the macular area.
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients
Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate
Technology, people key to improving health outcomes, driving revenue